Addex Therapeutics Ltd (ADXN) Stock Price & Analysis
Addex Therapeutics Ltd (ADXN) — MoonshotScore 18/100 (Weak band), calculated Nov 18, 2026. Price $3.40 (+11.11%), as of the Nov 19, 2026 trading session; market cap $5.96M.
Educational signal · not a buy or sell recommendation · How to read this
Addex Therapeutics Ltd · ADXN · NASDAQ
Addex Therapeutics Ltd is a development-stage biopharmaceutical company focused on small-molecule therapies for central nervous system (CNS) disorders. Its lead programs target Parkinson's disease, epilepsy, and addiction, leveraging G-protein coupled receptor modulation.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Addex Therapeutics (ADXN)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Slipping.
- quarterly revenue CHF 29,724 (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 1 of the last 8 reports
Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 17 | Weak | |
| 18 | Weak | |
| 18 | Weak | |
| 18 | Weak | |
| 18 | Weak | |
| 18 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $3.40 | |
| Change on the day | +11.11% | |
| 52-week range | $2.56 – $10.43 | |
| Market capitalisation | $5.96M | — |
| Price / earnings (trailing) | -1.01 | |
| Shares traded on the day | 18.3K |
Price & events
Other perspectives
Council score for Addex Therapeutics (ADXN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Addex Therapeutics (ADXN), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Addex Therapeutics Ltd (ADXN) is listed on NASDAQ. It employs 3 people and is led by Timothy Mark Dyer. In Q3 FY2025 it reported revenue of CHF 29,724 and net income of -CHF 2M. The market values it at $5.96M.
What do the latest results show for Addex Therapeutics (ADXN)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of CHF 29,724. Against analyst estimates the company has EPS beat 1 of the last 8 reports.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | CHF 29,724 | -CHF 2M | -CHF 1.68 (diluted) |
| Q4 FY2025 | CHF 248 | -CHF 2M | — |
What are the financial strengths and risks for Addex Therapeutics (ADXN)?
Short answer · as of
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Piotroski F 2. Trailing ratios: current ratio 0.76 · earnings yield -122.3% · free-cash-flow yield -58.2%.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Addex Therapeutics (ADXN)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $1.42M · EPS -4.74 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q3 FY2025) was filed Dec 4, 2025 — 11 months ago.
Checked against the records this page reads, on the dates shown above.
How does Addex Therapeutics compare with its peers?
Short answer
Addex Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| Addex Therapeutics (ADXN) — this page | $3.40 | $5.96M | 18 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $1.42M
- EPS estimate
- $-4.74
Measured against a quoted price of $3.40 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 11, 2026
- Transactions
- 44
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 0
- Other transactions
- 44
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ADXN in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ADXN in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Addex Therapeutics (ADXN)?
What Investors Ask About Addex Therapeutics (ADXN)
These answers are editorial: 1 of these 9 answers is drawn from the ADXN research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ADXN?
ADXN carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Addex Therapeutics Ltd is a development-stage biopharmaceutical company focused on small-molecule therapies for central nervous system (CNS) disorders.
Is ADXN a good stock to buy?
Stock Expert AI does not rate ADXN buy, sell or hold. Addex Therapeutics Ltd carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ADXN stock price today?
The last price recorded for Addex Therapeutics Ltd (ADXN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is Addex Therapeutics Ltd's primary therapeutic focus and scientific approach?
Addex Therapeutics Ltd primarily focuses on discovering, developing, and commercializing small-molecule pharmaceutical products for central nervous system (CNS) disorders. Its core scientific approach centers on the innovative use of oral small molecule allosteric modulators of G-protein coupled receptors (GPCRs).
What are the key factors to evaluate for ADXN?
Addex Therapeutics Ltd (ADXN) holds a MoonshotScore in the low range. Not financial advice.
How frequently does ADXN data refresh on this page?
ADXN's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ADXN's recent stock price performance?
Addex Therapeutics Ltd (ADXN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on G-protein coupled receptor (GPCR) allosteric modulation for CNS disorders. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ADXN overvalued or undervalued right now?
Addex Therapeutics Ltd (ADXN) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ADXN before investing?
Before investing in Addex Therapeutics Ltd (ADXN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 20 figures on this page — 9 from Financial Modeling Prep (FMP), 10 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com